Reference : Emerging therapies for ionizing radiation-associated skin field carcinogenesis.
Scientific journals : Article
Human health sciences : Dermatology
http://hdl.handle.net/2268/27944
Emerging therapies for ionizing radiation-associated skin field carcinogenesis.
English
Pierard, Gérald mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
Pierard, Claudine mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
Paquet, Philippe mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
Quatresooz, Pascale mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
2009
Expert Opinion on Pharmacotherapy
Ashley Publications Ltd
10
5
813-21
Yes (verified by ORBi)
International
1465-6566
1744-7666
London
United Kingdom
[en] Animals ; Antineoplastic Agents/therapeutic use ; Cryotherapy/trends ; Humans ; Neoplasms, Radiation-Induced/etiology/therapy ; Photochemotherapy/trends ; Radiation, Ionizing ; Skin Neoplasms/etiology/therapy
[en] BACKGROUND: Radiodermatitis in its acute and chronic presentations represents a set of specific adverse effects resulting from ionizing radiations. Skin-field cancerization is another condition associated to or independent of clinically recognizable radiodermatitis. This condition leads to the risk of later occurrence of skin malignancies. METHOD: Review of the current and most pertinent peer-reviewed publications with the addition of personal perspectives. RESULT/CONCLUSION: The presence of field cancerization encompasses subclinical changes, precursors of malignant alterations, as well as single or multiple primary neoplasms and local neoplastic recurrences. These tumours commonly require repeated treatments over time and cause significant morbidity. In general, specific tumour-directed treatments using ablative or destructive techniques require regular follow-up and screening for disclosing any further neoplasm. Another strategy corresponding to field-directed treatment targets a larger area of irradiated skin to reduce the risk of developing second neoplasms and local recurrences. Imiquimod is an immune response modifier of the imidazoquinoline class. It is the archetype drug used to control skin-field carcinogenesis. Cryotherapy, topical 5-fluorouracil, diclofenac and conventional photodynamic therapy are supposed to bring effects differing by their indications, healing rates and remission rates. The possibility of inducting a radiation recall dermatitis by some of these therapeutic modalities has not been thoroughly evaluated, and at present cannot be ruled out with confidence.
http://hdl.handle.net/2268/27944
10.1517/14656560902754060

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
EMERGING THERAPIES.pdfPublisher postprint339.32 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.